We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer

By LabMedica International staff writers
Posted on 20 Apr 2026

Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. More...

Identifying molecular drivers that tip tumors toward invasion and metastasis remains a clinical priority, and understanding how epidermal identity is maintained may help flag high-risk disease earlier. New findings now identify a protein safeguard that preserves epithelial programming and limits the transition to metastatic behavior.

Hebrew University of Jerusalem researchers identified WWOX as a molecular “protein shield” that preserves epithelial identity in cSCC. The study outlines how this protein functions as a primary defense against progression to aggressive disease. Loss of WWOX was linked to transformation of common skin cancer cells into invasive, poorly differentiated forms.

Mechanistically, WWOX stabilizes the p63 protein, a master regulator that maintains epithelial structure and function. When WWOX is intact, p63 remains stable and skin cells retain their identity. When WWOX is lost, p63 levels drop, triggering epithelial‑to‑mesenchymal transition (EMT) that endows cells with migratory properties, enabling invasion and dissemination to the lungs and other organs.

Using advanced genetic models alongside human tissue samples, the investigators showed that combined loss of WWOX and the tumor suppressor p53 markedly accelerated tumor onset. Tumors arising under double deficiency were earlier, more aggressive, and poorly differentiated compared with settings in which WWOX remained functional. In these models, 100% of subjects with dual WWOX–p53 loss developed tumors, versus a much lower percentage in control groups.

Analyses of human tissue microarrays supported the translational relevance: as cSCC advanced, WWOX and p63 levels declined in tandem. According to the authors, this correlation suggests both proteins could serve as clinical biomarkers to help predict which tumors are likely to become dangerous. The findings were published in Proceedings of the National Academy of Sciences under the title “WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.” The results further suggest that restoring WWOX, stabilizing p63, or promoting epithelial differentiation might inhibit EMT and slow tumor growth.

Related Links
Hebrew University of Jerusalem


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.